GlassScriptPhysician profile
David R Lerner
NPI 1194081729
$4,605.15
in general payments reported to CMS, 2019-2025
26 companies · $1,145 in 2025
The $1,145 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $800 · 2020: $211 · 2023: $135 · 2024: $2,314 · 2025: $1,145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,012 · Travel and Lodging: $1,582.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,011.58 |
| Travel and Lodging | $1,582.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,391.43 | 2019-2025 | Triclip, Mitraclip |
| Boston Scientific Corporation | $356.67 | 2019-2025 | Watchman Access System, Watchman Flx |
| Amgen INC. | $316.13 | 2019-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $181.21 | 2019-2024 | Lifevest |
| Medtronic, INC. | $171.23 | 2025 | Affera Mapping System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $167.51 | 2019-2025 | Jardiance |
| Biosense Webster, INC. | $155.99 | 2024 | Carto 3 |
| Integra Lifesciences Corporation | $129.21 | 2025 | Relieva Spinplus Nav, Trudi Probe, Inspira Air |
| Pfizer INC. | $119.78 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $73.03 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $60.51 | 2025 | Eliquis, Camzyos |
| Novartis Pharmaceuticals Corporation | $52.97 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $50.83 | 2019 | |
| Lundbeck LLC | $48.97 | 2019-2020 | |
| Cleerly, INC. | $48.00 | 2025 | Cleerly Ischemia, Cleerly Labs |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $37.02 | 2019 | |
| Bridgebio Pharma, INC. | $36.83 | 2025 | Attruby |
| Heartflow, INC. | $29.80 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $29.33 | 2019 | |
| Lantheus Medical Imaging, INC. | $27.67 | 2019 | |
| Alnylam Pharmaceuticals INC. | $26.48 | 2025 | Amvuttra |
| Therapeuticsmd, INC. | $25.83 | 2019 | |
| Altathera Pharmaceuticals LLC | $21.29 | 2025 | Sotalol Hydrochloride |
| Otsuka America Pharmaceutical, INC. | $19.06 | 2019 | |
| Genzyme Corporation | $15.77 | 2020 | |
| Daiichi Sankyo INC. | $12.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Lerner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.